HEALTHCARE News & Analysis

Find out how you can benefit from global megatrends. 

Shares in Australia's second biggest pathology operator have floundered in recent years. Shane Ponraj thinks better days could be ahead.

The steep market reaction comes after a recent announcement by the ACCC.

CSL's Behring division shone but markets were left underwhelmed by the company's guidance for 2025.

Shares are up 25% year to date but still screen as undervalued.

The shares are trading at a 27% discount to our fair value.

Morningstar analyst Shane Ponraj discusses the latest clinical trial results from Eli Lilly.

This week’s Investing Compass episode goes through what we can learn from top performing stocks. 

Morningstar sees several reasons to expect a stronger recover than market consensus.

The potential for weight loss drugs to impact the sleep apnea giant has weighed on the share price, though Morningstar analyst Shane Ponraj thinks...